UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Passive and active immunization against respiratory syncytial virus for the young and old

Expert review of vaccines, 2017-07, Vol.16 (7), p.737-749

2017

Volltextzugriff (PDF)

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2383504

2024

Volltextzugriff (PDF)

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein

mAbs, 2021-01, Vol.13 (1), p.1955812-1955812

2021

Volltextzugriff (PDF)

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2344970-2344970

2024

Volltextzugriff (PDF)

Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies

Expert review of vaccines, 2017-04, Vol.16 (4), p.351-360

2017

Volltextzugriff (PDF)

Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles

Human vaccines & immunotherapeutics, 2017-11, Vol.13 (11), p.2594-2605

2017

Volltextzugriff (PDF)

A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus

Human vaccines & immunotherapeutics, 2017-09, Vol.13 (9), p.2092-2097

2017

Volltextzugriff (PDF)

Protection of neonates and infants by maternal immunization

Expert review of vaccines, 2016-11, Vol.15 (11), p.1347-1349

2016

Volltextzugriff (PDF)

Current concepts and progress in RSV vaccine development

Expert review of vaccines, 2014-03, Vol.13 (3), p.333-344

2014

Volltextzugriff (PDF)

Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform

Human vaccines & immunotherapeutics, 2018-01, Vol.14 (1), p.59-66

2018

Volltextzugriff (PDF)

Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus

Expert review of vaccines, 2008-10, Vol.7 (8), p.1239-1255

2008

Volltextzugriff (PDF)

Respiratory syncytial virus vaccine development

Expert review of vaccines, 2011-10, Vol.10 (10), p.1415-1433

Hurwitz, Julia L

2011

Volltextzugriff (PDF)

The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development

Expert review of vaccines, 2012-12, Vol.11 (12), p.1441-1457

2012

Volltextzugriff (PDF)

Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan

Expert review of vaccines, 2024-01, Vol.23 (1), p.986-996

2024

Volltextzugriff (PDF)

Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis

Expert review of vaccines, 2016-02, Vol.15 (2), p.173-187

2016

Volltextzugriff (PDF)

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo

mAbs, 2018-04, Vol.10 (3), p.453-462

2018

Volltextzugriff (PDF)

Recent advances in the development of subunit-based RSV vaccines

Expert review of vaccines, 2016-01, Vol.15 (1), p.53-68

2016

Volltextzugriff (PDF)

A review of palivizumab and emerging therapies for respiratory syncytial virus

Expert opinion on biological therapy, 2011-11, Vol.11 (11), p.1455-1467

2011

Volltextzugriff (PDF)

Pharmacological management of human respiratory syncytial virus infection

Expert opinion on pharmacotherapy, 2020-12, Vol.21 (18), p.2293-2303

2020

Volltextzugriff (PDF)

Respiratory syncytial virus seasonality and its implications on prevention strategies

Human vaccines & immunotherapeutics, 2018-01, Vol.14 (1), p.234-244

2018

Volltextzugriff (PDF)

Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2365804

2024

Volltextzugriff (PDF)

Progress in the development of virus-like particle vaccines against respiratory viruses

Expert review of vaccines, 2020-01, Vol.19 (1), p.11-24

2020

Volltextzugriff (PDF)

Antibody response to respiratory syncytial virus infection in children <18 months old

Human vaccines & immunotherapeutics, 2016-07, Vol.12 (7), p.1700-1706

2016

Volltextzugriff (PDF)

A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2358566-2358566

2024

Volltextzugriff (PDF)

Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats

Human vaccines & immunotherapeutics, 2015-12, Vol.11 (12), p.2904-2912

2015

Volltextzugriff (PDF)

1 – 25 von 190

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

KollektionTaylor & Francis Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)
Mit Volltextzugriff
(141)

Publikationsform

Artikel
(190)

Sprache

Englisch
(190)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Passive and active immunization against respiratory syncytial virus for the young and old

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies

Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles

A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus

Protection of neonates and infants by maternal immunization

Current concepts and progress in RSV vaccine development

Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform

Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus

Respiratory syncytial virus vaccine development

The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development

Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults ≥60 years old in Japan

Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo

Recent advances in the development of subunit-based RSV vaccines

A review of palivizumab and emerging therapies for respiratory syncytial virus

Pharmacological management of human respiratory syncytial virus infection

Respiratory syncytial virus seasonality and its implications on prevention strategies

Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain

Progress in the development of virus-like particle vaccines against respiratory viruses

Antibody response to respiratory syncytial virus infection in children <18 months old

A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States

Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats

Aktive Filter

Suchergebnisse filtern